Skip to Main Content

Paper Details

Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
J Am Coll Surg
0
2023
HER2, HER2+, HER2+ Breast Cancer, HER2+ breast cancer, Multifocal/multicentric tumors, Paclitaxel, Patients, Pertuzumab, Trastuzumab, breast cancer, paclitaxel, patients, pertuzumab, trastuzumab, tumors
Author NameAffiliation
Anna WeissFrom the Harvard Medical School
Anna Weiss
Anna WeissDana-Farber Brigham Cancer Center
Ian E KropDana-Farber Brigham Cancer Center
Ian E KropFrom the Harvard Medical School
Ian E KropWaks) Dana-Farber Cancer Institute
Tari A KingDana-Farber Brigham Cancer Center
Tari A King
Sara M TolaneyFrom the Harvard Medical School
Sara M TolaneyDana-Farber Brigham Cancer Center
Sara M TolaneyWaks) Dana-Farber Cancer Institute
Eric P WinerFrom the Harvard Medical School
Eric P WinerDana-Farber Brigham Cancer Center
Eric P WinerWaks) Dana-Farber Cancer Institute
  • 1 - 14

Datasets

Release 1.2